Literature DB >> 17922053

Retrospective analysis of the prognostic role of tissue eosinophil and mast cells in Hodgkin's lymphoma.

Katalin Keresztes1, Zoltan Szollosi, Zsofia Simon, Ilona Tarkanyi, Zoltan Nemes, Arpad Illes.   

Abstract

The composition of reactive cell populations, which constitute the majority of tumor load in Hodgkin's lymphoma (HL), can influence the prognosis of the disease. Besides widely accepted and applied prognostic scores, the authors evaluate biological factors that may have a prognostic impact. Previous data indicate that the rate of eosinophils and mast cells in the reactive cell population, determined already at diagnosis, can be used for this purpose. Histological samples from 104 patients with HL with an average follow-up period of 110 (24-214) months were retrospectively analyzed. Mast cell positivity was associated with better overall survival, although this difference was only of borderline statistical significance (p=0.092). No significant difference was found in parameters like overall survival (OS, p=0.906) or event-free survival (EFS, p=0.307) of eosinophil-positive vs. -negative cases or in EFS (p=0.742) of mast cell-positive vs. -negative individuals (criterion for a positive specimen was more than 5% of appropriate cells in the reactive cell population). Looking at the effect of eosinophilia and mastocytosis together, there was no significant difference between the subgroups categorized according to the combined presence of the two cell types. It seems that tissue eosinophil and mast cell predominance have no prognostic value that could be used in clinical practice, although a tendency for correlation of mast cell positivity with overall survival could be seen. For a definitive statement, multicenter studies should be performed involving a higher number of patients suffering from HL.

Entities:  

Mesh:

Year:  2007        PMID: 17922053     DOI: 10.1007/bf02893504

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  26 in total

1.  Tissue eosinophilia in relation to immunopathological and clinical characteristics in Hodgkin's disease.

Authors:  U Axdorph; A Porwit-MacDonald; G Grimfors; M Björkholm
Journal:  Leuk Lymphoma       Date:  2001 Sep-Oct

Review 2.  [Eosinophils and antitumour response].

Authors:  R Costello; T O'Callaghan; G Sébahoun
Journal:  Rev Med Interne       Date:  2005-03-17       Impact factor: 0.728

Review 3.  The role of cytokines in classical Hodgkin lymphoma.

Authors:  Brian F Skinnider; Tak W Mak
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

Review 4.  Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis.

Authors:  Daniel Molin
Journal:  Ups J Med Sci       Date:  2004       Impact factor: 2.384

5.  Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils.

Authors:  F Jundt; I Anagnostopoulos; K Bommert; F Emmerich; G Müller; H D Foss; H D Royer; H Stein; B Dörken
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

6.  Eosinophil predominance in Hodgkin's disease.

Authors:  J Tóth; O Dworák; J Sugár
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1977-05-20

7.  Eosinophils are the major source of transforming growth factor-beta 1 in nodular sclerosing Hodgkin's disease.

Authors:  M Kadin; J Butmarc; A Elovic; D Wong
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

8.  Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group.

Authors:  M Henry-Amar; S Friedman; M Hayat; R Somers; J H Meerwaldt; P Carde; J M Burgers; J Thomas; M Monconduit; E M Noordijk
Journal:  Ann Intern Med       Date:  1991-03-01       Impact factor: 25.391

9.  Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin interferes with the growth of tumor cells through a mechanism involving fibroblasts.

Authors:  Michael Samoszuk; Emi Kanakubo; John K Chan
Journal:  BMC Cancer       Date:  2005-09-21       Impact factor: 4.430

10.  Do mast cells help to induce angiogenesis in B-cell non-Hodgkin's lymphomas?

Authors:  D Ribatti; B Nico; A Vacca; A Marzullo; N Calvi; L Roncali; F Dammacco
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more
  5 in total

Review 1.  Eosinophils: The unsung heroes in cancer?

Authors:  Gilda Varricchi; Maria Rosaria Galdiero; Stefania Loffredo; Valeria Lucarini; Giancarlo Marone; Fabrizio Mattei; Gianni Marone; Giovanna Schiavoni
Journal:  Oncoimmunology       Date:  2017-11-13       Impact factor: 8.110

2.  Role of mast cells in fibrosis of classical Hodgkin lymphoma.

Authors:  Shoko Nakayama; Taiji Yokote; Nobuya Hiraoka; Uta Nishiwaki; Toshiaki Hanafusa; Yasuichiro Nishimura; Motomu Tsuji
Journal:  Int J Immunopathol Pharmacol       Date:  2016-04-19       Impact factor: 3.219

3.  Tumor-associated tissue eosinophilia predicts favorable clinical outcome in solid tumors: a meta-analysis.

Authors:  Guoming Hu; Shimin Wang; Kefang Zhong; Feng Xu; Liming Huang; Wei Chen; Pu Cheng
Journal:  BMC Cancer       Date:  2020-05-20       Impact factor: 4.430

Review 4.  The Hodgkin Lymphoma Immune Microenvironment: Turning Bad News into Good.

Authors:  Victoria Menéndez; José L Solórzano; Sara Fernández; Carlos Montalbán; Juan F García
Journal:  Cancers (Basel)       Date:  2022-03-07       Impact factor: 6.639

Review 5.  Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab.

Authors:  David J Jackson; Stephanie Korn; Sameer K Mathur; Peter Barker; Venkata G Meka; Ubaldo J Martin; James G Zangrilli
Journal:  Drug Saf       Date:  2020-05       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.